Takizawa, D.; Arai, H.; Shibasaki, M.; Tamura, Y.; Kakizaki, S.; Hatanaka, T.; Naganuma, A.; Ueno, T.; Fukuchi, T.; Namikawa, M.;
et al. Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Curr. Oncol. 2026, 33, 159.
https://doi.org/10.3390/curroncol33030159
AMA Style
Takizawa D, Arai H, Shibasaki M, Tamura Y, Kakizaki S, Hatanaka T, Naganuma A, Ueno T, Fukuchi T, Namikawa M,
et al. Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology. 2026; 33(3):159.
https://doi.org/10.3390/curroncol33030159
Chicago/Turabian Style
Takizawa, Daichi, Hirotaka Arai, Mitsuhiko Shibasaki, Yuki Tamura, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Naganuma, Takashi Ueno, Toru Fukuchi, Masashi Namikawa,
and et al. 2026. "Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma" Current Oncology 33, no. 3: 159.
https://doi.org/10.3390/curroncol33030159
APA Style
Takizawa, D., Arai, H., Shibasaki, M., Tamura, Y., Kakizaki, S., Hatanaka, T., Naganuma, A., Ueno, T., Fukuchi, T., Namikawa, M., Takakusagi, S., Saito, S., Suga, T., Tojima, H., Yamazaki, Y., & Uraoka, T.
(2026). Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology, 33(3), 159.
https://doi.org/10.3390/curroncol33030159
